Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) reported a remarkable 475% revenue growth year-to-date for the nine months ending March 31, 2022. The company achieved A$2 million in cash receipts in Q3, primarily from EasyDNA product sales. Key advancements include the launch of the geneType Multi-Risk Test with NATA accreditation and CMS certification, alongside a US patent for the COVID-19 Risk Test. The company maintains a healthy cash balance of A$11.43 million, which provides a 21-month runway for growth initiatives. CEO Simon Morriss highlighted the company's strong position for future commercialization.

Positive

• Revenue growth of 475% year-to-date.
• Cash receipts of A$2 million in Q3, up 9% from the previous quarter.
• geneType Multi-Risk Test received NATA accreditation and CMS certification.
• US Patent granted for COVID-19 Risk Test, expanding commercialization opportunities.
• Strong cash balance of A$11.43 million, ensuring 21 months of operational runway.

Negative

• None.

MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022.

Key Highlights

• Year to date growth in revenue of 475%
• Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product sales
• GeneType Multi-Risk Test received NATA accreditation and CMS certification
• Phase 1 of geneType Multi-Risk Test launched for physicians targeting 50% of annual mortalities and morbidities in six serious diseases including: breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and type-2 diabetes
• US Patent granted for COVID-19 Risk Test, enabling GENE to expand commercialization opportunities
• Leveraging EasyDNA acquisition by progressing a ‘One company two brands’ strategy
• Launched our Virtual Sales Rep (VSR) with Hahn Healthcare in Australian General Practice with sales supporting the creation of our geneType Hubs
• Sound cash balance of A$11.43 million, providing 21 months runway for investing in growth initiative

Genetic Technologies is in a strong position, with important progress made during the March ’22 quarter on two of the Company’s core geneType growth products. The geneType Multi-Risk Test receiving approval for commercial release, while the US Patent Office granted a US patent for the geneType COVID-19 Risk Test.

CEO Simon Morriss stated: “These approvals mark an important step for the Company to initiate the commercialization of the Multi-Risk Test to physicians in Australia and the USA. We are also very pleased to announce the granting of a US patent for our COVID-19 Risk Test, which provides a strong foundation for the ongoing commercialization of this test to provide improved outcomes for patients at risk of developing severe COVID-19 disease.”

The Future of Precision Medicine – Genetic Multi-Risk Test
During February 2022, the Company’s geneType Multi-Risk Test received simultaneous NATA accreditation and CLIA certification from the US Centers for Medicare and Medicaid Services (CMS). These critical approvals have enabled the commercial launch of Multi-Risk Test and represents an important step towards the development of personalized, preventative healthcare, enabling patients and their healthcare professionals to develop a long-term health plan.

The Company’s strategy to commence commercialization and enhance the product distribution network is well underway. The initial launch phase will focus on risk assessments for six serious diseases that together represent around half of all annual morbidities in the US⁵: Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type-2 Diabetes. The tests will be available to purchase individually or as a bundle. Additional disease candidates will follow in planned future phases.

Game-Changing Commercialization and Reimbursement Strategies for GeneType
Reimbursement - USA
GENE has engaged US based consulting company, ALVA10, to determine the level of evidence required for US payers (e.g. Medicare and large US employer groups) to provide coverage for diagnostic tests. ALVA10 is in the final stages of developing a Budget Impact Model (BIM) that can translate our geneType breast cancer risk assessment test into a format that can be assessed within the US healthcare system. This is our first step towards obtaining US payers coverage, which would be a ‘game-changing’ achievement for GENE, facilitating and accelerating broad adoption of geneType.

Initial feedback from the BIM shows implementation of the geneType breast cancer risk assessment test increases supplemental screening and an increase in early-stage detection from 54% to 61% of cases, with potential savings of US$83k per patient by moving from a cancer stage (2b or later) to earlier stage diagnosis. The BIM will be completed in the coming quarter, including the drafting of a manuscript in support of reimbursement and commercialization model for payers and insurers to review.

Australian Sales Strategy
Hahn Healthcare has been engaged and launched our Virtual Sales Rep (VSR) in the Australian General Practice with sales management support targeting 2,000 general practice clinics with > 6 GPs which represent > 80% of all consultations. Our goal is to develop clinical practices into 40-50 “geneType Hubs”. With the support of our clinical and medical team, we have developed an “Early Access Program” enabling clinical practices to offer their first 10 patients testing at no-charge. GENE is optimistic that the combination of geneType’s strong predictive clinical utility and Hahn Healthcare’s deep reach into Australian medical centers will accelerate adoption and drive growth of the test in the Australian market.

US Patent Office Grants Patent for COVID-19 Risk Test
During the March 2022 quarter, GENE was granted a US patent for the geneType COVID-19 Risk Test covering the proprietary technology incorporated in the test. This marks an important step for the Company to secure commercial opportunities for the geneType COVID-19 Risk Test, which predicts disease severity by using genetic and clinical information to provide a risk score that can be used to understand a person’s risk of contracting a serious case of COVID-19.

According to the Centers for Disease Control and Prevention, only 71.2% of the US population is fully vaccinated, leaving approximately 95 million Americans partially or completely unvaccinated. The test could assist people to better understand their risk of severe disease, while providing those who are vaccinated with an understanding of the necessity to obtain a booster if they are at high risk of severe disease. In the coming quarter, our Scientific team is preparing manuscripts for publication to support clinical validity for each of the tests in the phase 1 launch of the Multi-Risk Test.

Outlook
Commenting on the forward outlook, Simon Morriss stated, “We are very pleased with the progress made over the last quarter in achieving approvals for Multi-Risk Test and the patent for the COVID-19 Risk Test. Quarter four focus will be on the significant opportunity of our geneType product suite; continuing to demonstrate the clinical validity and utility of the geneType tests in the healthcare sector; and EasyDNA sales growth by expanding our product offering through new markets and channels.”

Investor Relations                                
Hugh Morgan                                        
Market Eye                                        
M: +61 407 453 109                                
E: hugh.morgan@marketeye.com.au                

About Genetic Technologies Limited
Genetic Technologies Limited (NASDAQ: GENE; ASX: GTG) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products.

For more information, please visit www.genetype.com

^{______________________________
1} National Association of Test Authorities, Australia
² US Centers for Medicare and Medicaid Services
³ Excludes A$1.44m R&D Tax Incentive received on April 2, 2022
⁴ Based on latest Company cashflow projections
⁵ https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm

FAQ

What was the revenue growth reported by Genetic Technologies Limited (GENE)?

Genetic Technologies Limited reported a remarkable 475% revenue growth year-to-date for the nine months ending March 31, 2022.

How much cash did Genetic Technologies (GENE) receive in Q3?

In the third quarter, Genetic Technologies received cash receipts of A$2 million, a 9% increase from the prior quarter.

What certifications did the geneType Multi-Risk Test receive?

The geneType Multi-Risk Test received NATA accreditation and CMS certification, allowing for its commercial launch.

What is the significance of the US Patent granted to Genetic Technologies (GENE)?

The US Patent granted for the COVID-19 Risk Test expands commercialization opportunities for Genetic Technologies.

What is the cash position of Genetic Technologies (GENE)?

Genetic Technologies reported a strong cash balance of A$11.43 million, providing approximately 21 months of operational runway.